Sutro Biopharma Key Executives
This section highlights Sutro Biopharma's key executives, including their titles and compensation details.
Find Contacts at Sutro Biopharma
(Showing 0 of )
Sutro Biopharma Earnings
This section highlights Sutro Biopharma's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
$0.58
Stock Price
$48.55M
Market Cap
310
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for Sutro Biopharma, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $62.04M | $153.73M | $67.77M | $61.88M | $42.72M |
| Cost of Revenue | $- | $6.82M | $8.29M | $9.77M | $76.96M |
| Gross Profit | $62.04M | $146.91M | $59.48M | $52.11M | $-34.24M |
| Gross Profit Ratio | 100.00% | 95.57% | 87.77% | 84.21% | -80.14% |
| Research and Development Expenses | $252.04M | $180.43M | $137.17M | $104.40M | $76.96M |
| General and Administrative Expenses | $48.45M | $62.58M | $59.54M | $56.00M | $36.82M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $48.45M | $62.58M | $59.54M | $56.00M | $36.82M |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $300.50M | $243.01M | $196.72M | $160.40M | $113.78M |
| Cost and Expenses | $300.50M | $243.01M | $196.72M | $160.40M | $113.78M |
| Interest Income | $44.42M | $14.51M | $3.46M | $577.00K | $1.51M |
| Interest Expense | $31.07M | $23.75M | $3.35M | $3.14M | $4.08M |
| Depreciation and Amortization | $7.22M | $6.82M | $8.29M | $9.77M | $4.30M |
| EBITDA | $-186.81M | $-67.92M | $-105.07M | $-98.52M | $-23.75M |
| EBITDA Ratio | -301.10% | -44.18% | -155.03% | -159.22% | -55.60% |
| Operating Income | $-238.45M | $-89.28M | $-128.94M | $-98.52M | $-71.06M |
| Operating Income Ratio | -384.34% | -58.07% | -190.26% | -159.22% | -166.32% |
| Total Other Income Expenses Net | $13.36M | $677.00K | $12.24M | $-7.01M | $38.93M |
| Income Before Tax | $-225.10M | $-88.60M | $-116.70M | $-105.54M | $-32.13M |
| Income Before Tax Ratio | -362.81% | -57.63% | -172.20% | -170.55% | -75.20% |
| Income Tax Expense | $2.36M | $18.19M | $2.50M | $3.14M | $4.08M |
| Net Income | $-227.46M | $-106.79M | $-119.20M | $-108.67M | $-36.20M |
| Net Income Ratio | -366.62% | -69.47% | -175.89% | -175.62% | -84.75% |
| EPS | $-2.96 | $-1.78 | $-2.35 | $-2.36 | $-1.11 |
| EPS Diluted | $-2.96 | $-1.78 | $-2.35 | $-2.36 | $-1.11 |
| Weighted Average Shares Outstanding | 76.83M | 60.16M | 50.74M | 46.12M | 32.57M |
| Weighted Average Shares Outstanding Diluted | 76.83M | 60.16M | 50.74M | 46.12M | 32.57M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.81M | $8.52M | $25.71M | $13.01M | $113.72M | $16.92M | $10.41M | $12.67M | $8.63M | $25.15M | $28.10M | $5.90M | $10.65M | $8.52M | $28.05M | $14.66M | $8.28M | $17.82M | $9.47M | $7.15M |
| Cost of Revenue | $- | $- | $62.02M | $1.76M | $1.73M | $1.74M | $2.40M | $2.26M | $2.16M | $2.08M | $2.05M | $29.99M | $2.40M | $26.60M | $25.31M | $22.56M | $22.74M | $19.36M | $17.24M | $17.62M |
| Gross Profit | $14.81M | $8.52M | $-36.31M | $11.25M | $111.99M | $15.19M | $8.02M | $10.42M | $6.47M | $23.07M | $26.04M | $-24.09M | $8.25M | $-18.09M | $2.74M | $-7.90M | $-14.46M | $-1.54M | $-7.77M | $-10.47M |
| Gross Profit Ratio | 100.00% | 100.00% | -141.27% | 86.46% | 98.48% | 89.72% | 77.00% | 82.20% | 75.00% | 91.72% | 92.69% | -408.56% | 77.45% | -212.34% | 9.77% | -53.90% | -174.68% | -8.63% | -82.10% | -146.35% |
| Research and Development Expenses | $71.04M | $62.11M | $62.02M | $56.88M | $53.77M | $45.67M | $41.59M | $39.40M | $43.13M | $31.71M | $32.33M | $29.99M | $29.93M | $26.60M | $25.31M | $22.56M | $22.74M | $19.36M | $17.24M | $17.62M |
| General and Administrative Expenses | $9.03M | $14.33M | $12.37M | $12.72M | $16.80M | $15.27M | $15.00M | $15.51M | $14.72M | $14.64M | $15.14M | $15.04M | $15.76M | $16.59M | $12.54M | $11.11M | $10.38M | $9.08M | $8.64M | $8.71M |
| Selling and Marketing Expenses | $- | $- | $- | $-1.76M | $-1.73M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $9.03M | $14.33M | $12.37M | $10.96M | $15.07M | $15.27M | $15.00M | $15.51M | $14.72M | $14.64M | $15.14M | $15.04M | $15.76M | $16.59M | $12.54M | $11.11M | $10.38M | $9.08M | $8.64M | $8.71M |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $80.07M | $76.44M | $74.39M | $67.84M | $68.84M | $60.94M | $56.59M | $54.91M | $57.85M | $46.36M | $47.48M | $45.03M | $45.69M | $43.19M | $37.85M | $33.67M | $33.12M | $28.44M | $25.89M | $26.33M |
| Cost and Expenses | $80.07M | $76.44M | $74.39M | $69.60M | $70.57M | $60.94M | $56.59M | $54.91M | $57.85M | $46.36M | $47.48M | $45.03M | $45.69M | $43.19M | $37.85M | $33.67M | $33.12M | $28.44M | $25.89M | $26.33M |
| Interest Income | $3.86M | $27.04M | $4.91M | $4.10M | $4.56M | $4.55M | $2.84M | $2.56M | $2.13M | $1.01M | $197.00K | $116.00K | $96.00K | $109.00K | $175.00K | $197.00K | $188.00K | $295.00K | $384.00K | $641.00K |
| Interest Expense | $8.69M | $7.91M | $9.04M | $9.40M | $8.73M | $8.68M | $3.36M | $2.99M | $- | $2.79M | $594.00K | $657.00K | $612.00K | $820.00K | $847.00K | $858.00K | $- | $2.32M | $2.96M | $1.06M |
| Depreciation and Amortization | $1.87M | $1.80M | $1.79M | $1.76M | $1.73M | $1.74M | $2.40M | $2.26M | $2.16M | $2.08M | $2.05M | $2.00M | $2.40M | $4.96M | $1.12M | $1.29M | $1.17M | $967.00K | $1.06M | $1.10M |
| EBITDA | $-59.53M | $-39.08M | $-38.93M | $-49.27M | $44.88M | $-39.47M | $-35.14M | $-46.90M | $-32.44M | $-14.62M | $-20.86M | $-36.46M | $-35.11M | $-25.12M | $-4.18M | $-28.21M | $-58.37M | $-10.75M | $-17.16M | $-17.44M |
| EBITDA Ratio | -401.99% | -458.66% | -151.46% | -378.75% | 39.47% | -233.22% | -337.46% | -370.04% | -375.76% | -58.13% | -74.26% | -618.23% | -329.55% | -294.97% | -14.92% | -192.43% | -705.15% | -60.32% | -181.20% | -243.85% |
| Operating Income | $-65.26M | $-67.92M | $-48.69M | $-56.59M | $43.15M | $-44.01M | $-46.18M | $-42.24M | $-49.22M | $-21.21M | $-19.38M | $-39.13M | $-35.04M | $-34.67M | $-9.80M | $-19.01M | $-24.84M | $-10.62M | $-16.42M | $-19.18M |
| Operating Income Ratio | -440.66% | -797.17% | -189.39% | -435.05% | 37.95% | -260.07% | -443.52% | -333.26% | -570.23% | -84.34% | -68.97% | -663.59% | -328.85% | -407.12% | -34.96% | -129.67% | -300.11% | -59.57% | -173.38% | -268.18% |
| Total Other Income Expenses Net | $-4.83M | $19.13M | $675.00K | $-1.62M | $3.72M | $-3.43M | $7.81M | $-7.42M | $14.63M | $1.72M | $-4.13M | $22.00K | $-3.09M | $3.77M | $3.65M | $-11.35M | $-34.70M | $27.76M | $46.29M | $-415.00K |
| Income Before Tax | $-70.09M | $-48.79M | $-48.01M | $-58.21M | $46.87M | $-47.45M | $-38.37M | $-49.66M | $-34.59M | $-19.49M | $-23.51M | $-39.11M | $-38.12M | $-30.90M | $-6.15M | $-30.36M | $-59.54M | $17.14M | $29.87M | $-19.59M |
| Income Before Tax Ratio | -473.28% | -572.62% | -186.77% | -447.52% | 41.22% | -280.34% | -368.55% | -391.79% | -400.76% | -77.50% | -83.68% | -663.22% | -357.85% | -362.83% | -21.93% | -207.09% | -719.30% | 96.16% | 315.47% | -273.98% |
| Income Tax Expense | $2.35M | $- | $8.00K | $1.72M | $15.81M | $1.84M | $151.00K | $395.00K | $2.50M | $-1.72M | $2.50M | $-22.00K | $612.00K | $820.00K | $847.00K | $858.00K | $-2.25M | $2.32M | $2.96M | $641.00K |
| Net Income | $-72.44M | $-48.79M | $-48.02M | $-58.21M | $31.07M | $-49.28M | $-38.52M | $-50.05M | $-37.09M | $-17.77M | $-26.01M | $-39.09M | $-38.12M | $-30.90M | $-6.15M | $-30.36M | $-59.54M | $17.14M | $29.87M | $-19.59M |
| Net Income Ratio | -489.18% | -572.62% | -186.80% | -447.52% | 27.32% | -291.21% | -370.00% | -394.90% | -429.73% | -70.65% | -92.58% | -662.85% | -357.85% | -362.83% | -21.93% | -207.09% | -719.30% | 96.16% | 315.47% | -273.98% |
| EPS | $-0.94 | $-0.59 | $-0.59 | $-0.95 | $0.51 | $-0.81 | $-0.64 | $-0.85 | $-0.65 | $-0.34 | $-0.55 | $-0.84 | $-0.83 | $-0.67 | $-0.13 | $-0.66 | $-1.61 | $0.46 | $1.00 | $-0.84 |
| EPS Diluted | $-0.94 | $-0.59 | $-0.59 | $-0.95 | $0.51 | $-0.81 | $-0.64 | $-0.85 | $-0.65 | $-0.34 | $-0.55 | $-0.84 | $-0.83 | $-0.67 | $-0.13 | $-0.66 | $-1.61 | $0.45 | $0.94 | $-0.84 |
| Weighted Average Shares Outstanding | 76.83M | 82.04M | 81.22M | 61.46M | 61.01M | 60.60M | 60.34M | 58.72M | 56.79M | 52.35M | 46.96M | 46.50M | 46.01M | 46.12M | 46.12M | 45.91M | 36.89M | 36.89M | 29.90M | 23.20M |
| Weighted Average Shares Outstanding Diluted | 76.83M | 82.04M | 81.22M | 61.46M | 61.01M | 60.60M | 60.34M | 58.72M | 56.79M | 52.35M | 46.96M | 46.50M | 46.16M | 46.16M | 46.12M | 45.91M | 36.89M | 37.88M | 31.78M | 23.20M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $190.30M | $69.27M | $47.25M | $30.41M | $206.15M |
| Short Term Investments | $126.59M | $306.35M | $287.11M | $167.52M | $161.99M |
| Cash and Short Term Investments | $316.89M | $375.62M | $302.34M | $197.94M | $368.14M |
| Net Receivables | $8.62M | $36.08M | $7.12M | $12.45M | $5.56M |
| Inventory | $- | $- | $-11.67M | $1 | $- |
| Other Current Assets | $17.80M | $9.85M | $11.67M | $8.12M | $4.49M |
| Total Current Assets | $343.31M | $421.54M | $309.47M | $218.51M | $378.18M |
| Property Plant Equipment Net | $35.87M | $44.76M | $51.06M | $51.59M | $12.94M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $32.02M | $68.78M | $872.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $8.03M | $4.44M | $14.39M | $2.53M | $2.12M |
| Total Non-Current Assets | $43.90M | $49.19M | $97.48M | $122.89M | $15.93M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $387.21M | $470.74M | $406.94M | $341.41M | $394.11M |
| Account Payables | $10.47M | $9.44M | $4.80M | $6.01M | $5.54M |
| Short Term Debt | $7.48M | $10.48M | $21.67M | $11.45M | $- |
| Tax Payables | $18.00K | $15.16M | $- | $- | $- |
| Deferred Revenue | $69.78M | $20.67M | $106.64M | $5.50M | $14.60M |
| Other Current Liabilities | $44.14M | $37.99M | $23.32M | $18.78M | $9.45M |
| Total Current Liabilities | $131.89M | $93.75M | $139.47M | $41.74M | $29.60M |
| Long Term Debt | $15.67M | $23.15M | $33.34M | $46.96M | $24.55M |
| Deferred Revenue Non-Current | $- | $202.49M | $89.89M | $- | $6.10M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $1.34M |
| Other Non-Current Liabilities | $195.04M | $1.69M | $119.00K | $146.00K | $1.82M |
| Total Non-Current Liabilities | $210.71M | $227.34M | $50.43M | $47.11M | $32.47M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $342.61M | $321.09M | $189.90M | $88.84M | $62.06M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $83.00K | $61.00K | $58.00K | $46.00K | $46.00K |
| Retained Earnings | $-786.87M | $-559.41M | $-452.62M | $-333.41M | $-227.87M |
| Accumulated Other Comprehensive Income Loss | $39.00K | $21.00K | $-618.00K | $-314.00K | $129.00K |
| Other Total Stockholders Equity | $831.35M | $708.98M | $670.22M | $586.24M | $559.75M |
| Total Stockholders Equity | $44.60M | $149.65M | $217.05M | $252.56M | $332.05M |
| Total Equity | $44.60M | $149.65M | $217.05M | $252.56M | $332.05M |
| Total Liabilities and Stockholders Equity | $387.21M | $470.74M | $406.94M | $341.41M | $394.11M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $387.21M | $470.74M | $406.94M | $341.41M | $394.11M |
| Total Investments | $126.59M | $306.35M | $287.11M | $236.30M | $161.99M |
| Total Debt | $23.15M | $33.63M | $67.52M | $57.37M | $24.55M |
| Net Debt | $-167.15M | $-35.63M | $20.26M | $26.96M | $-181.61M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $190.30M | $174.58M | $90.79M | $65.22M | $69.27M | $81.83M | $235.09M | $251.47M | $47.25M | $96.78M | $79.11M | $28.90M | $30.41M | $30.71M | $56.39M | $55.82M | $206.15M | $64.37M | $65.35M | $43.56M |
| Short Term Investments | $126.59M | $213.68M | $335.20M | $248.00M | $306.35M | $273.32M | $156.55M | $25.03M | $287.11M | $227.47M | $146.52M | $180.24M | $167.52M | $198.99M | $202.31M | $195.41M | $161.99M | $216.86M | $185.11M | $71.83M |
| Cash and Short Term Investments | $316.89M | $388.25M | $425.99M | $313.22M | $375.62M | $355.15M | $391.64M | $276.49M | $334.36M | $324.25M | $225.64M | $209.15M | $197.94M | $229.70M | $258.70M | $251.23M | $368.14M | $281.23M | $250.46M | $115.39M |
| Net Receivables | $8.62M | $6.66M | $6.95M | $31.30M | $36.08M | $16.63M | $10.00M | $9.87M | $7.12M | $11.24M | $97.67M | $11.69M | $12.45M | $12.33M | $9.16M | $7.23M | $5.56M | $7.48M | $5.10M | $9.08M |
| Inventory | $- | $- | $- | $1 | $1 | $1 | $- | $-17.70M | $1 | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $1 | $- |
| Other Current Assets | $17.80M | $10.87M | $10.53M | $10.06M | $9.85M | $9.48M | $10.34M | $17.70M | $11.67M | $11.06M | $8.20M | $7.91M | $8.12M | $8.70M | $9.75M | $7.55M | $4.49M | $3.58M | $2.93M | $5.98M |
| Total Current Assets | $343.31M | $405.78M | $443.48M | $354.58M | $421.54M | $381.25M | $411.99M | $286.37M | $353.15M | $346.55M | $331.51M | $228.74M | $218.51M | $250.73M | $277.62M | $266.00M | $378.18M | $292.30M | $258.49M | $127.46M |
| Property Plant Equipment Net | $35.87M | $38.02M | $39.75M | $42.22M | $44.76M | $46.34M | $48.77M | $49.83M | $51.06M | $51.35M | $51.32M | $51.66M | $51.59M | $53.45M | $18.67M | $14.83M | $12.94M | $11.95M | $11.27M | $9.53M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $857.00K | $- | $-34.04M | $-33.35M | $163.97M | $-32.02M | $- | $- | $20.70M | $68.78M | $64.28M | $60.01M | $74.61M | $- | $- | $5.65M | $14.19M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $8.03M | $8.03M | $5.82M | $5.74M | $4.44M | $38.18M | $37.49M | $-142.15M | $34.75M | $2.79M | $2.79M | $2.58M | $2.53M | $3.02M | $3.50M | $3.08M | $2.99M | $2.99M | $2.14M | $2.70M |
| Total Non-Current Assets | $43.90M | $46.05M | $45.57M | $48.82M | $49.19M | $50.48M | $52.91M | $71.65M | $53.79M | $54.15M | $54.11M | $74.93M | $122.89M | $120.74M | $82.17M | $92.53M | $15.93M | $14.94M | $19.05M | $26.42M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $387.21M | $451.83M | $489.04M | $403.40M | $470.74M | $431.73M | $464.90M | $358.02M | $406.94M | $400.70M | $385.62M | $303.68M | $341.41M | $371.47M | $359.79M | $358.53M | $394.11M | $307.24M | $277.54M | $153.88M |
| Account Payables | $10.47M | $6.22M | $6.09M | $7.51M | $9.44M | $5.53M | $3.86M | $5.06M | $4.80M | $12.44M | $12.57M | $10.71M | $6.01M | $11.17M | $7.64M | $5.89M | $5.54M | $4.88M | $4.90M | $5.84M |
| Short Term Debt | $7.48M | $14.41M | $13.87M | $6.67M | $16.90M | $19.48M | $22.07M | $23.74M | $21.67M | $17.76M | $14.74M | $14.66M | $11.45M | $9.14M | $3.12M | $- | $- | $- | $- | $- |
| Tax Payables | $18.00K | $- | $11.00K | $15.16M | $15.16M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $69.78M | $72.56M | $73.96M | $20.50M | $20.67M | $23.98M | $18.04M | $102.23M | $16.76M | $15.92M | $6.49M | $6.28M | $5.50M | $7.80M | $8.13M | $12.09M | $14.60M | $15.70M | $23.50M | $22.87M |
| Other Current Liabilities | $44.14M | $38.11M | $36.06M | $29.66M | $31.57M | $24.61M | $23.17M | $13.50M | $23.32M | $9.53M | $9.65M | $6.04M | $18.78M | $5.89M | $7.23M | $4.68M | $9.45M | $9.33M | $7.06M | $3.30M |
| Total Current Liabilities | $131.89M | $131.29M | $129.99M | $79.51M | $93.75M | $73.61M | $67.12M | $126.04M | $66.55M | $58.29M | $44.57M | $38.76M | $41.74M | $35.45M | $26.12M | $22.66M | $29.60M | $29.91M | $35.46M | $32.01M |
| Long Term Debt | $15.67M | $17.66M | $19.59M | $177.86M | $23.15M | $24.86M | $26.53M | $28.07M | $33.34M | $37.82M | $41.85M | $44.40M | $46.96M | $50.79M | $21.69M | $24.68M | $24.55M | $24.41M | $24.28M | $24.16M |
| Deferred Revenue Non-Current | $193.34M | $- | $21.69M | $46.31M | $53.38M | $220.92M | $216.53M | $85.05M | $89.89M | $74.73M | $90.00M | $- | $- | $145.00K | $193.00K | $822.00K | $6.10M | $8.37M | $10.56M | $15.11M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $21.40M | $23.15M | $-142.76M | $-136.65M | $- | $- | $- | $- | $- | $- | $- | $3.43M | $2.39M | $1.34M | $280.00K | $330.00K | $373.00K |
| Other Non-Current Liabilities | $1.69M | $191.66M | $165.60M | $48.01M | $150.81M | $142.76M | $136.65M | $- | $119.00K | $133.00K | $142.00K | $147.00K | $146.00K | $1.50M | $4.28M | $3.03M | $1.82M | $431.00K | $478.00K | $514.00K |
| Total Non-Current Liabilities | $210.71M | $209.32M | $206.88M | $225.87M | $227.34M | $245.78M | $243.06M | $46.56M | $123.35M | $112.69M | $131.99M | $44.54M | $47.11M | $52.44M | $26.16M | $28.53M | $32.47M | $33.21M | $35.32M | $39.78M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $342.61M | $340.61M | $336.87M | $305.38M | $321.09M | $319.39M | $310.18M | $172.60M | $189.90M | $170.97M | $176.56M | $83.30M | $88.84M | $87.89M | $52.29M | $51.19M | $62.06M | $63.12M | $70.78M | $71.79M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $83.00K | $82.00K | $82.00K | $62.00K | $61.00K | $61.00K | $60.00K | $60.00K | $58.00K | $55.00K | $49.00K | $47.00K | $46.00K | $46.00K | $46.00K | $46.00K | $46.00K | $38.00K | $36.00K | $23.00K |
| Retained Earnings | $-786.87M | $-714.43M | $-665.64M | $-617.62M | $-559.41M | $-590.47M | $-541.19M | $-502.67M | $-452.62M | $-418.02M | $-398.53M | $-372.52M | $-333.41M | $-295.29M | $-264.38M | $-258.23M | $-227.87M | $-168.33M | $-185.47M | $-215.34M |
| Accumulated Other Comprehensive Income Loss | $39.00K | $106.00K | $-163.00K | $-113.00K | $21.00K | $7.00K | $16.00K | $-107.00K | $-618.00K | $-1.34M | $-1.36M | $-1.15M | $-314.00K | $-30.00K | $-45.00K | $0 | $129.00K | $237.00K | $398.00K | $28.00K |
| Other Total Stockholders Equity | $831.35M | $825.46M | $817.90M | $715.70M | $708.98M | $702.75M | $695.83M | $688.12M | $670.22M | $649.03M | $608.90M | $594.00M | $586.24M | $578.85M | $571.88M | $565.52M | $559.75M | $412.17M | $391.79M | $297.37M |
| Total Stockholders Equity | $44.60M | $111.22M | $152.18M | $98.02M | $149.65M | $112.35M | $154.72M | $185.41M | $217.05M | $229.73M | $209.06M | $220.37M | $252.56M | $283.58M | $307.50M | $307.34M | $332.05M | $244.12M | $206.76M | $82.08M |
| Total Equity | $44.60M | $111.22M | $152.18M | $98.02M | $149.65M | $112.35M | $154.72M | $185.41M | $217.05M | $229.73M | $209.06M | $220.37M | $252.56M | $283.58M | $307.50M | $307.34M | $332.05M | $244.12M | $206.76M | $82.08M |
| Total Liabilities and Stockholders Equity | $387.21M | $451.83M | $489.04M | $403.40M | $470.74M | $431.73M | $464.90M | $358.02M | $406.94M | $400.70M | $385.62M | $303.68M | $341.41M | $371.47M | $359.79M | $358.53M | $394.11M | $307.24M | $277.54M | $153.88M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $387.21M | $451.83M | $489.04M | $403.40M | $470.74M | $431.73M | $464.90M | $358.02M | $406.94M | $400.70M | $385.62M | $303.68M | $341.41M | $371.47M | $359.79M | $358.53M | $394.11M | $307.24M | $277.54M | $153.88M |
| Total Investments | $126.59M | $213.68M | $335.20M | $248.86M | $306.35M | $239.27M | $123.20M | $188.99M | $255.09M | $227.47M | $146.52M | $200.94M | $199.12M | $263.27M | $262.32M | $270.02M | $161.99M | $216.86M | $190.76M | $86.02M |
| Total Debt | $23.15M | $24.86M | $26.53M | $184.53M | $182.75M | $38.17M | $42.66M | $46.56M | $50.43M | $52.95M | $55.47M | $57.97M | $57.37M | $58.48M | $24.82M | $24.68M | $24.55M | $24.41M | $24.28M | $24.16M |
| Net Debt | $-167.15M | $-149.72M | $-64.26M | $119.32M | $113.48M | $-43.66M | $-192.44M | $-204.90M | $3.18M | $-43.83M | $-23.65M | $29.07M | $26.96M | $27.77M | $-31.57M | $-31.14M | $-181.61M | $-39.96M | $-41.07M | $-19.41M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-227.46M | $-106.79M | $-119.20M | $-105.54M | $-32.13M |
| Depreciation and Amortization | $7.22M | $6.82M | $5.69M | $4.84M | $4.30M |
| Deferred Income Tax | $- | $- | $- | $7.24M | $-41.01M |
| Stock Based Compensation | $24.69M | $24.91M | $26.30M | $23.24M | $11.92M |
| Change in Working Capital | $8.90M | $-34.38M | $104.41M | $-17.62M | $-11.49M |
| Accounts Receivables | $27.46M | $-28.96M | $5.34M | $-6.89M | $739.00K |
| Inventory | $- | $- | $- | $-4.54M | $-58.00K |
| Accounts Payables | $706.00K | $4.81M | $-1.23M | $6.43M | $-947.00K |
| Other Working Capital | $-19.27M | $-10.23M | $100.29M | $-12.61M | $-11.22M |
| Other Non Cash Items | $-4.88M | $-2.17M | $-13.65M | $6.16M | $606.00K |
| Net Cash Provided by Operating Activities | $-191.54M | $-111.62M | $3.55M | $-81.68M | $-67.80M |
| Investments in Property Plant and Equipment | $-3.10M | $-4.32M | $-7.86M | $-15.32M | $-7.13M |
| Acquisitions Net | $- | $- | $28.74M | $- | $- |
| Purchases of Investments | $-461.52M | $-460.30M | $-216.67M | $-248.73M | $-130.74M |
| Sales Maturities of Investments | $683.13M | $460.69M | $189.50M | $166.73M | $138.38M |
| Other Investing Activities | $- | $- | $-28.73M | $9.00K | $89.00K |
| Net Cash Used for Investing Activities | $218.51M | $-3.92M | $-35.02M | $-97.31M | $604.00K |
| Debt Repayment | $-4.08M | $-12.50M | $-9.38M | $- | $15.00M |
| Common Stock Issued | $96.53M | $11.97M | $56.27M | $- | $251.41M |
| Common Stock Repurchased | $- | $- | $- | $-7.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.61M | $138.08M | $1.42M | $3.26M | $2.83M |
| Net Cash Used Provided by Financing Activities | $94.05M | $137.55M | $48.31M | $3.26M | $269.25M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $121.02M | $22.01M | $16.84M | $-175.74M | $202.05M |
| Cash at End of Period | $191.16M | $70.14M | $48.13M | $31.29M | $207.02M |
| Cash at Beginning of Period | $70.14M | $48.13M | $31.29M | $207.02M | $4.97M |
| Operating Cash Flow | $-191.54M | $-111.62M | $3.55M | $-81.68M | $-67.80M |
| Capital Expenditure | $-3.10M | $-4.32M | $-7.86M | $-15.32M | $-7.13M |
| Free Cash Flow | $-194.64M | $-115.93M | $-4.31M | $-97.00M | $-74.93M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-72.44M | $-48.79M | $-48.02M | $-58.21M | $31.07M | $-49.28M | $-38.52M | $-50.05M | $-34.59M | $-19.49M | $-26.01M | $-39.11M | $-38.12M | $-30.90M | $-6.15M | $-30.36M | $-59.54M | $17.14M | $29.87M | $-19.59M |
| Depreciation and Amortization | $1.87M | $1.80M | $1.79M | $1.76M | $1.73M | $1.74M | $1.73M | $1.61M | $1.53M | $1.44M | $1.40M | $1.33M | $1.31M | $1.12M | $1.12M | $1.29M | $1.17M | $967.00K | $1.06M | $1.10M |
| Deferred Income Tax | $- | $- | $- | $- | $-25.08M | $-3.09M | $-10.16M | $- | $- | $- | $- | $- | $3.37M | $-3.69M | $-3.63M | $11.19M | $37.34M | $-29.54M | $-48.77M | $-34.00K |
| Stock Based Compensation | $5.92M | $6.54M | $6.16M | $6.07M | $6.22M | $6.00M | $6.66M | $6.02M | $5.85M | $6.78M | $6.70M | $6.97M | $6.89M | $6.50M | $5.91M | $3.95M | $3.09M | $3.11M | $3.01M | $2.71M |
| Change in Working Capital | $-15.73M | $-7.12M | $48.37M | $-16.62M | $-21.58M | $3.74M | $7.88M | $-24.41M | $19.57M | $79.98M | $10.09M | $-5.22M | $3.13M | $-1.46M | $-2.77M | $-16.53M | $2.19M | $-10.79M | $10.00K | $-2.89M |
| Accounts Receivables | $-1.96M | $295.00K | $24.35M | $4.78M | $-19.45M | $-6.63M | $-126.00K | $-2.75M | $4.13M | $86.43M | $-85.98M | $768.00K | $-124.00K | $-3.17M | $-1.93M | $-1.67M | $1.92M | $-2.38M | $3.98M | $-2.78M |
| Inventory | $- | $- | $- | $- | $-12.90M | $2.88M | $10.02M | $- | $- | $- | $- | $- | $830.00K | $-544.00K | $-1.50M | $-3.33M | $-134.00K | $-986.00K | $390.00K | $417.00K |
| Accounts Payables | $4.12M | $-123.00K | $-1.40M | $-1.90M | $4.06M | $1.41M | $-857.00K | $198.00K | $-937.00K | $-1.12M | $1.97M | $-1.13M | $1.95M | $2.74M | $2.20M | $-462.00K | $-231.00K | $1.25M | $-1.97M | $255.00K |
| Other Working Capital | $-17.89M | $-7.29M | $25.42M | $-19.50M | $-6.19M | $6.08M | $-1.16M | $-21.86M | $16.37M | $-5.33M | $94.10M | $-4.86M | $477.00K | $-487.00K | $-1.53M | $-11.07M | $627.00K | $-8.68M | $-2.39M | $-783.00K |
| Other Non Cash Items | $8.66M | $-16.95M | $1.15M | $8.97M | $21.71M | $7.39M | $1.23M | $5.83M | $-16.21M | $-2.85M | $4.65M | $777.00K | $1.84M | $4.04M | $255.00K | $28.00K | $-3.12M | $1.42M | $2.32M | $-19.00K |
| Net Cash Provided by Operating Activities | $-71.74M | $-64.52M | $9.46M | $-64.74M | $14.07M | $-33.50M | $-31.20M | $-60.99M | $-23.86M | $65.85M | $-3.19M | $-35.26M | $-21.58M | $-24.41M | $-5.26M | $-30.43M | $-18.88M | $-17.69M | $-12.50M | $-18.73M |
| Investments in Property Plant and Equipment | $-1.07M | $-828.00K | $-756.00K | $-446.00K | $-1.44M | $-328.00K | $-1.60M | $-942.00K | $-3.37M | $-738.00K | $-2.20M | $-1.55M | $-2.54M | $-5.00M | $-5.41M | $-2.38M | $-1.62M | $-2.98M | $-1.77M | $-763.00K |
| Acquisitions Net | $- | $- | $- | $- | $22.07M | $113.69M | $-67.76M | $-68.39M | $28.74M | $77.30M | $-50.12M | $- | $15.69M | $- | $- | $- | $- | $- | $- | $763.00K |
| Purchases of Investments | $-126.03M | $-43.16M | $-157.33M | $-135.00M | $-80.57M | $-238.37M | $-88.60M | $-52.76M | $-102.17M | $-99.56M | $-3.94M | $-10.99M | $-22.62M | $-23.79M | $-37.71M | $-164.60M | $-16.74M | $-22.73M | $-87.67M | $-3.60M |
| Sales Maturities of Investments | $214.59M | $117.23M | $77.71M | $199.55M | $58.50M | $124.68M | $156.36M | $121.16M | $67.65M | $22.26M | $54.06M | $45.53M | $45.93M | $26.55M | $49.00M | $45.25M | $34.09M | $26.00M | $32.30M | $46.00M |
| Other Investing Activities | $- | $74.05M | $- | $64.55M | $-22.07M | $-113.69M | $67.76M | $68.39M | $-28.73M | $-77.30M | $50.12M | $34.53M | $-15.68M | $2.75M | $11.29M | $-119.35M | $89.00K | $3.27M | $-55.37M | $-763.00K |
| Net Cash Used for Investing Activities | $87.49M | $147.29M | $-80.38M | $64.11M | $-23.51M | $-114.02M | $66.16M | $67.45M | $-37.88M | $-78.04M | $47.91M | $32.98M | $20.78M | $-2.24M | $5.88M | $-121.73M | $15.81M | $296.00K | $-57.14M | $41.64M |
| Debt Repayment | $- | $- | $- | $-4.08M | $-3.12M | $-3.12M | $-3.12M | $-3.12M | $-3.12M | $-3.12M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $15.00M |
| Common Stock Issued | $- | $-26.03M | $96.53M | $1.03M | $-954.00K | $954.00K | $1.05M | $10.92M | $15.35M | $32.33M | $8.60M | $1.16M | $- | $1.54M | $-39.00K | $2.23M | $143.16M | $17.40M | $- | $- |
| Common Stock Repurchased | $- | $374.00K | $- | $-374.00K | $490.00K | $-33.00K | $- | $- | $- | $- | $- | $-404.00K | $-7.00K | $-580.00K | $- | $-407.00K | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-24.00K | $1.02M | $-37.00K | $654.00K | $- | $-2.62M | $139.74M | $960.00K | $1.00K | $642.00K | $-3.11M | $760.00K | $513.00K | $963.00K | $-39.00K | $1.83M | $1.69M | $-128.00K | $91.42M | $702.00K |
| Net Cash Used Provided by Financing Activities | $-24.00K | $1.02M | $96.49M | $-3.43M | $-3.12M | $-5.74M | $137.66M | $8.76M | $12.22M | $29.85M | $5.49M | $760.00K | $506.00K | $963.00K | $-39.00K | $1.83M | $144.85M | $17.27M | $91.42M | $15.70M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $15.73M | $84.65M | $25.57M | $-4.05M | $-12.57M | $-153.26M | $172.62M | $15.22M | $-49.52M | $17.66M | $50.21M | $-1.51M | $-293.00K | $-25.68M | $574.00K | $-150.33M | $141.78M | $-121.00K | $21.78M | $38.60M |
| Cash at End of Period | $191.16M | $175.44M | $90.79M | $65.22M | $69.27M | $82.71M | $235.97M | $63.34M | $48.13M | $97.65M | $79.99M | $29.77M | $31.29M | $31.58M | $57.26M | $56.69M | $207.02M | $65.24M | $65.36M | $43.58M |
| Cash at Beginning of Period | $175.44M | $90.79M | $65.22M | $69.27M | $81.83M | $235.97M | $63.34M | $48.13M | $97.65M | $79.99M | $29.77M | $31.29M | $31.58M | $57.26M | $56.69M | $207.02M | $65.24M | $65.36M | $43.58M | $4.97M |
| Operating Cash Flow | $-71.74M | $-64.52M | $9.46M | $-64.74M | $14.07M | $-33.50M | $-31.20M | $-60.99M | $-23.86M | $65.85M | $-3.19M | $-35.26M | $-21.58M | $-24.41M | $-5.26M | $-30.43M | $-18.88M | $-17.69M | $-12.50M | $-18.73M |
| Capital Expenditure | $-1.07M | $-828.00K | $-756.00K | $-446.00K | $-1.44M | $-328.00K | $-1.60M | $-942.00K | $-3.37M | $-738.00K | $-2.20M | $-1.55M | $-2.54M | $-5.00M | $-5.41M | $-2.38M | $-1.62M | $-2.98M | $-1.77M | $-763.00K |
| Free Cash Flow | $-72.81M | $-65.34M | $8.70M | $-65.19M | $12.63M | $-33.83M | $-32.80M | $-61.93M | $-27.23M | $65.12M | $-5.39M | $-36.81M | $-24.12M | $-29.40M | $-10.68M | $-32.81M | $-20.50M | $-20.66M | $-14.27M | $-19.50M |
Sutro Biopharma Dividends
Explore Sutro Biopharma's dividend history, including dividend yield, payout ratio, and historical payments.
Sutro Biopharma News
Read the latest news about Sutro Biopharma, including recent articles, headlines, and updates.
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - - The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater -
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will present at the TD Cowen 45th Annual Health Care Conference taking place March 3-5, 2025 in Boston, MA.
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA.
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows promising efficacy in ovarian cancer, with manageable toxicity, positioning it for potential Accelerated Approval by mid-2027. Financially, STRO has a two-year runway with current cash reserves, but further financing may be needed, risking shareholder dilution.
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations at the 15th Annual World ADC Conference, taking place in San Diego, November 4-6, 2024.
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-P1, the registration-directed study of luveltamab tazevibulin (luvelta) for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), has been initiated and is open for enrollment.
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
STRO specializes in ADCs for oncology, leveraging XpressCF and XpressCF+ platforms for precise antibody-drug conjugates without living cells. STRO-002, a promising ADC for ovarian cancer, has shown favorable safety and efficacy in trials, with potential FDA approval by 2026-2027. Collaborations with Merck, Vaxcyte, and Astellas Pharma could generate up to $3 billion in milestone payments.
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug conjugates (ADCs), today announced that on September 16, 2024, the Compensation Committee of Sutro's Board of Directors granted 60,000 restricted stock units (RSUs) of Sutro common stock to a new employee. The grant was made as an inducement material to the employee's acceptance of employment with Sutro and was approved by the Compensation Committee of Sutro's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose (RP2D) -
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research Forum to highlight its pipeline of next-generation ADCs. The live webcast will be held on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET.
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-L1, the global Phase 2 study of luveltamab tazevibulin (luvelta) for patients with non-small cell lung cancer (NSCLC) whose tumor expresses Folate Receptor-α (FRα), has been initiated and is open for enrollment. Initial data from this study is expected in the first half of 2025.
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 -
VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline
CONROE, Texas , June 3, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, has entered into a strategic partnership with Sutro Biopharma, Inc. (Sutro) to support clinical production of luveltamab tazevibulin, abbreviated as "luvelta", a novel Folate Receptor-α (FRα)-targeting antibody-drug conjugate (ADC) with the potential to address the unmet need in several FRα-expressing cancers. Sutro, a clinical-stage oncology company pioneering site-specific and novel-format ADCs, has just initiated the randomized portion (Part 2) of REFRαME-O1, a global, registration-directed clinical trial of luvelta (NCT05870748) in platinum-resistant ovarian cancer (PROC).
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 -
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share. The gross proceeds from this offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about April 4, 2024, subject to the satisfaction of customary closing conditions.
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO, “Sutro”, “the Company”) today announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages of pre-clinical development, targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including solid tumors and hematological malignancies.1 The agreement gives Ipsen exclusive worldwide rights to develop and commercialize STRO-003 and will be the first ADC candidate joining Ipsen's expanding portfolio.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for STRO.